^
Association details:
| Biomarker: | TMB-H |
|---|---|
| Cancer: | Thyroid Gland Medullary Carcinoma |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Alkylating agent-induced high tumor mutational burden in MTC and response to immune checkpoint inhibitors: Two case reports
Published date:
09/12/2023
Excerpt:
We describe two patients with metastatic MTC who developed a hypermutant phenotype after alkylating agent treatment. This phenotype was characterized by a high tumor mutational burden (TMB) and a mutational signature indicative of alkylating agent mutagenesis (Single Base Substitution 11). Both patients received immune checkpoint inhibitors, with partial morphological responses, clinical benefit and PFS of 6 and 9 months respectively.
DOI:
10.1089/thy.2023.0144